Fresh Patents
Monitor Patents Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents Browse Locations
06/25/09 - Class 435 site info News monitor Monitor Keywords monitor archive Archive organizer Organizer account info Account |  435 rss/xml feed | Prev - Next

Baalc expression as a diagnostic marker for acute leukemia

Abstract: Overexpression of the gene, BAALC, in biological samples from a patient is prognostic for tumor aggressiveness and unfavorable patient outcome. The present invention provides polynucleotide primers and probes for assaying for overexpression of BAALC transcripts. Kits containing the primers and probes are also provided. Also provided are antibodies for assaying for overexpression of BAALC proteins as well as peptide immunogens for producing the anti-BAALC antibodies. The present invention also provides methods for characterizing acute myelogenous leukemia, chronic myelogenous leukemia and prostate cancer in a patient, base on detection of BAALC overexpression. (end of abstract)


Agent: Calfee Halter & Griswold, LLP - Cleveland, OH, US
Inventors: Stephan M. Tanner, Stephan M. Tanner, Albert de la Chapelle, Albert de la Chapelle
USPTO Applicaton #: #20090162852 - Class: 435 6 (USPTO)

Baalc expression as a diagnostic marker for acute leukemia description/claims


The Patent Description & Claims data below is from USPTO Patent Application 20090162852, Baalc expression as a diagnostic marker for acute leukemia.

Full Patent Description - Patent Application Claims  monitor keywords

This application is a divisional of and claims priority to U.S. application Ser. No. 10/293,239, filed on Nov. 12, 2002, which claims priority to U.S. Provisional Application Ser. No. 60/348,210, filed Nov. 9, 2001, both of which are incorporated by reference herein in their entirety.

This invention was made, at least in part, with government support under National Institutes of Health Grant No. 5P30CA016058. The U.S. government has certain rights in the invention.

BACKGROUND

Leukemias comprise approximately 2% of adult cancers and are a heterogeneous group. There are two broad categories of leukemias. Acute leukemias arise when there is a block in the normal differentiation of cells to mature blood cells that results in large accumulations of immature cells or blasts in the blood. Examples of such cancers are acute myelogenous leukemia (AML; other names are acute myeloid leukemia and acute nonlymphocytic leukemia) and acute lymphoblastic leukemia (ALL). In chronic leukemia, on the other hand, there is unregulated proliferation of cells that have differentiated to mature blood cells. Examples of such cancers are chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML). CML has a chronic phase which then progresses to a phase called blast crisis where immature, blast cells are present in the blood. Both acute and chronic leukemias involve the myeloid cells of the bone marrow, including white cells, red cells, megakaryocytes and cells of the lymphoid lineage.

The cytogenetics of many leukemias are characterized by balanced chromosomal translocations that give rise to gene rearrangements. In acute myeloid leukemia (AML) for example, about 55% of adult de novo cases have clonal cytogenetic abnormalities, many of which are specific translocations. However, in the remaining cases, no visible cytogenetic abnormalities are found, although genetic changes are detected methods other than cytogenetics. In adult acute lymphoblastic leukemia (ALL), the proportion of patients with no cytogenetic abnormality is about 31%.

Tumors of the central nervous system (CNS) comprise primary brain tumors, primary intraspinal tumors, and tumors that metastasize to the CNS. Brain tumors comprise astrocytomas, glioblastomas, medulloblastomas, and others. An extracranial pediatric tumor, neuroblastoma, arises in pluripotent neural crest cells of the sympathetic nervous system.

Prostate cancer is an epithelial cell cancer of men. Most are adenocarcinomas. Tumorigenesis progresses from normal to hyperplasic prostate to well and poorly differentiated carcinoma.

Many cancers, including leukemias, CNS and prostate cancers suffer from the problem of late detection in patients. Also, even when such cancers are detected in a patient, it is often difficult to predict lifespan of, or to determine the optimal therapy for, the particular cancer in the particular patient. However, cancers are genetic diseases that are associated with changes in cellular DNA (i.e., genetic changes). Because occurrence of such DNA changes precedes the appearance of phenotypic changes characteristic of cancer cells, it is advantageous to use detection of such early genetic changes as an aid to cancer diagnosis. Also, because a single cancer type, as identified phenotypically or pathologically, may include cancers that can be subgrouped based on classification of genetic changes therein, detection of these genetic changes may provide improved patient prognosis and selection of more efficacious therapy, based on the subgroupings.

Although the specific genetic changes associated with some cancers are known, in other cancers the associated genetic changes are not known. Even if the genetic changes are not known, it may be possible to identify additional molecular changes resulting from the genetic changes contributing to cancer. For example, a genetic change in a cancer cell may result in changes in gene expression (i.e., transcription and/or translation) of multiple genes in a cancer cell. A gene which is not normally expressed in a particular cell type may come to be expressed in cancer cells, or a gene that is expressed at low levels in normal cells may come to be expressed at high levels in cancer cells. Such gene expression changes may be diagnostically and prognostically useful alone or may be used together with already identified cancer-associated genetic and gene expression changes in multivariate analysis for purposes of prognosis and selection of effective anticancer therapy.



Full Patent Description - Patent Application Claims
Click on the above for other options relating to this Baalc expression as a diagnostic marker for acute leukemia patent application.

Patent Applications in related categories:

20100062440 - markers for cancer - The present invention relates to novel markers for hypermethylation of gene promoters in cancers. In particular the present invention relates to a method of determining whether a tumour is developing in the aero-digestive system, or whether a subject is relapsing after treatment of such a tumour. The method comprises determining ...

20100062426 - Agr2 and tff3 regulation in the diagnosis and treatment of cancer - A method for assessing tumor progression is described by assessing AGR2 and/or TFF3 expression in a biological sample after induction of a physiological stress, such as hypoxia or serum deprivation in an enriched sample. Assessing the role of these indicators and their expression levels in an enriched CTC sample provides ...

20100062424 - Assessment of infectious bacteria - Disclosed herein are methods for determining whether an opportunistic bacterium is infectious. ...

20100062441 - C-met mutations and uses thereof - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-Met. ...

20100062425 - Cat allergen - The invention relates to a method for determining the level of Fel d1 expression in a cat, the method comprising: a) typing one or more polymorphic positions of the Fel d1 gene in a sample from the cat; and b) thereby determining the level of Fel d1 expression. ...

20100062442 - Cell detection - In one aspect the present invention provides a method of identifying a cell or cell colony which produces a polypeptide of interest, the method comprising exposing one or more cells to a marker compound which associates with a reference polypeptide, wherein production of the polypeptide of interest by the cells ...

20100062445 - Chromosome 1p36 polymorphisms and low bone mineral density - The invention provides methods and compositions for diagnosing risk of low BMD and risk of osteoporosis based on the detection of SNP identity for human chromosome 1p36 polymorphisms designated in the NCBI SNP database (dbSNP) as rs2794328, rs446529, rs397559 and rs1802353. ...

20100062434 - Detection of chromosomal inversions - A method and a kit for the identification of chromosomal inversions is described. Chromosomal inversions are difficult to detect unless they are quite large. The improved ability to detect chromosomal inversions is important to a number of medical applications, such as cancer and birth defects, as examples. Reporter species are ...

20100062429 - Fluorochromes for organelle tracing and multi-color imaging - Provided are compounds, methods and kits for identifying in cells of interest organelles including nuclei and a wide variety of organelles other than nuclei (non-nuclear organelles), as well as cell regions or cell domains. These compounds and methods can be used with other conventional detection reagents for identifying the location ...

20100062423 - Fret probes for fluorescent detection of the esps gene - The present invention relates to a primer pair for the detection of a specific gene, and more particularly to a probe pair for the detection and analysis of an EPSPS (5-enolpyruvylshikimate-3-phosphate synthase) gene, in which primers complementary to the base sequences in the EPSPS gene are labeled with fluorophores acting ...

20100062433 - Kit for detection/quantification of analyte, and method for detection/quantification of analyte - Disclosed are a detection/quantification kit and a detection/quantification method for detecting/quantifying an analyte rapidly at a low cost and in a simple manner. Specifically, disclosed is a kit for detecting an analyte in a sample, comprising a first conjugate and a second conjugate, wherein the first conjugate comprises a first ...

20100062430 - Method and kit for molecular chromosomal quantification - Diagnosis of chromosomal abnormalities or genetic disorders is performed using at least two marker sequences, wherein one marker sequence is a sequence known to be present on the chromosome or in the gene of interest, another marker sequence is a sequence known to be present on an autosomal chromosome, and ...

20100062439 - Method for detecting cyst nematodes - The present invention relates to a method for determining the presence of a cyst nematode in a sample comprising the steps of : providing a pair of bidirectional oligonucleotide primers or an oligonucleotide probe that hybridizes specifically, under stringent hybridization conditions, to a nucleic acid sequence encoding the SSU rRNA ...

20100062427 - Method for detecting disease-associated mutations - A method is described for diagnosing individuals as having hypertrophic cardiomyopathy, e.g. familial or sporadic hypertrophic cardiomyopathy. The method provides a useful diagnostic tool which becomes particularly important when testing asymptomatic individuals suspected of having the disease. Symptomatic individuals have a much better chance of being diagnosed properly by a ...

20100062432 - Method of detecting or quantitating endogenous wheat dna and method of determining contamination rate of genetically modified wheat in test sample - An object of the present invention is to discover an endogenous wheat sequence satisfying the conditions of: a) it is universally present in varieties of wheat, b) the amount present (detected amount) is not affected depending on the wheat variety, c) even if other grains are present, only wheat can ...

20100062428 - Methods for collecting and detecting oligonucleotides - Methods, pharmaceutical compositions, and kits are provided which includes accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, atherosclerotic disease, or neurological disease in ...

20100062436 - Methods for detection of a single- or double-stranded nucleic acid molecule - d) detecting whether or not the capture probe is hybridized to the nucleic acid molecule or part thereof. k) allowing the capture probe to react with the nucleic acid molecule or a part thereof; and j) ...

20100062447 - Methods for identifying cancer risk - The present invention provides methods and kits for identifying an increased risk of developing cancer in a subject. The methods include analyzing a first biological sample, such as a blood sample, from the subject for loss of imprinting of the IGF2 gene. According to the methods a loss of imprinting ...

20100062435 - Methods for stem cell production and therapy - The present invention relates to methods for rapidly expanding a stem cell population with or without culture supplements in simulated microgravity conditions. The present invention relates to methods for rapidly increasing the life span of stem cell populations without culture supplements in simulated microgravity conditions. The present invention also relates ...

20100062443 - Methods for the diagnosis and treatment of lung cancer - The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition. ...

20100062438 - Natural selection and cellular immortality - The invention provides new insights into the manner in which cells evolve and age thereby providing methods for assessing and studying those processes. ...

20100062422 - Optical component for observing a nanometric sample, system comprising same, analysis method using same, and uses thereof - The invention concerns an optical component for observing a sample, which includes a substrate and at least one complex index layer of predetermined thickness, designed to show a high intensity or color contrast for optical path variations, reliefs, nanometric thicknesses and diameters when it is observed by incoherent light reflection ...

20100062437 - Parallel profilling of signaling pathways - Methods for identifying signaling pathways that regulate the expression of a test gene are provided. ...

20100062448 - Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases - The present invention is based on the discovery that ζPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ζPKC gene expression in arthritic ...

20100062446 - Reactor plate and reaction processing method - Disclosed herein is a reactor plate which prevents the entry of foreign matter from the outside and the pollution of an outside environment. The reactor plate includes sealed reaction wells (5), reaction well channels (13, 15, 17) connected to the reaction wells (5), a sealed well (35) provided separately from ...

20100062444 - Tle3 as a marker for chemotherapy - Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer. ...

20100062431 - Use of adamts4 gene and protein polymorphisms - The use of the single nucleotide polymorphism (SNP) of the ADAMTS4 gene for the identification of cardiovascular and peripheral vascular disorders or of an increased risk for developing cardiovascular and peripheral vascular disorders in a biological sample taken from an individual to be examined; the use of ADAMTS4 for identifying ...


###
monitor keywords

Other recent patent applications listed under the agent Calfee Halter & Griswold, LLP:

20090308113 - Locker lock


How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Baalc expression as a diagnostic marker for acute leukemia or other areas of interest.
###


Previous Patent Application:
Affinity tag nucleic acid and protein compositions, and processes for using same
Next Patent Application:
Biological substance detection cartridge,biological substance detection apparatus, and biological substance detection method
Industry Class:
Chemistry: molecular biology and microbiology

###

FreshPatents.com Support
Thank you for viewing the Baalc expression as a diagnostic marker for acute leukemia patent info.
AAPL - Apple, BA - Boeing, CALP, DTV - Direct TV, EBAY, FRX, GOOG - Google, HEPH, IBM, JBL - Jabil, KO - Coca Cola, LXRX, MOT - Motorla IP-related news and info


Results in 1.88718 seconds


Other interesting Feshpatents.com categories:
Daimler Chrysler , DirecTV , Exxonmobil Chemical Company , Goodyear , Intel , Kyocera Wireless , paws
PATENT INFO
About this Page
noimage